Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
Bayer
Modality
UNKNOWN
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03119116CT.gov Use of Direct Oral Anticoagulants in UK | — | Completed | — | — | — |
NCT02784717CT.gov Xarelto on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in China: A Non-interventional Study | — | Completed | — | — | — |
NCT02313909CT.gov Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS) | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Stroke Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bay 59-7939 (this asset) | Bayer | P3 | CCC · 52 |
| Incobotulinumtoxina | Parc de Salut Mar | P4 | BBB |
| Aggrenox | Boehringer Ingelheim | P4 | BBB |
| Atenolol | Northern California Institute of Research and Education | P4 | BBB |
| Dextromethorphan | University of Florida | P4 | BBB |
| Tenecteplase | Assistance Publique - Hôpitaux de Paris | P4 | BBB |
| Nerinetide | NoNO Inc. | P3 | BBB |
| Rivaroxaban | China National Center for Cardiovascular Diseases | P4 | BBB |
| Aspirin | China National Center for Cardiovascular Diseases | P4 | BB |
+42 more in the Stroke Disorder cohort
Other indications for Bay 59-7939
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Atrial Fibrillation | — | P3 | BB · 66 |
| Pulmonary Embolism | — | Unk | D · 30 |
| Acute Coronary Syndrome | — | Unk | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Bay 59-7939 in Stroke Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bay-59-7939-stroke-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →